Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVACURE-2 TIL cell therapy in newly diagnosed advanced ovarian cancer
NL-OMON58720Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GC101 TIL + pembrolizumab and aldesleukin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Leiden University Medical Center. Primary endpoints: Immunotherapy-related grade III/IV NCI-CTC toxicity and Dose-limiting toxicities. Started Sep 2026; status: recruiting.
02
Drugs
GC101 TIL + pembrolizumabaldesleukin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON58720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58720.